Cardiff Oncology, Inc.
CRDF
$1.82
$0.010.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.85M | -50.42M | -51.02M | -48.85M | -45.43M |
| Total Depreciation and Amortization | 904.00K | 912.00K | 924.00K | 935.00K | 943.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.85M | 4.79M | 4.75M | 4.42M | 4.16M |
| Change in Net Operating Assets | 2.18M | 2.50M | 3.50M | 750.00K | 2.63M |
| Cash from Operations | -37.92M | -42.22M | -41.85M | -42.75M | -37.69M |
| Capital Expenditure | -44.00K | -44.00K | -26.00K | 0.00 | -80.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.39M | -4.85M | -24.46M | -5.49M | 13.81M |
| Cash from Investing | 1.34M | -4.90M | -24.49M | -5.49M | 13.73M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.58M | 44.22M | 51.62M | 53.68M | 53.78M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.58M | 44.22M | 51.62M | 53.68M | 53.78M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -34.00M | -2.90M | -14.72M | 5.44M | 29.82M |